Search
forLearn
5 / 801 resultslearn octapeptide-2
learn PTD-DBM
learn Ceramide A2
learn ACETYL TETRAPEPTIDE-2
Research
5 / 1000+ resultsresearch Co-expression of PADI isoforms during progenitor differentiation enables functional diversity
Different PADI isoforms help cells develop diverse functions.
research 부챗말 Glucopyranosyldiacylglycerol의 탈모방지 효능
Padina arborescens and its component MOGG may help prevent hair loss through several actions, including blocking a hair loss-related enzyme.
research Successful Immunsuppression in Childhood Alopecia Areata
Immunosuppression therapy with methylprednisolone effectively treats childhood alopecia areata.
research A BRIEF STUDY ON ALOPECIA AREATA
Alopecia areata causes hair loss with varied treatment responses and frequent relapses.
research Wirkung von Testosteron auf Haut und Haare
Testosterone affects skin by increasing oil production and influences hair growth.
Community Join
5 / 1000+ resultscommunity Pelage have presented only phase 2a. The rest of phase 2 for PP405 will be presented at a later medical meeting
PP405's phase 2a trial results were presented, focusing on safety and pharmacokinetics, with a future meeting planned to share the full dataset. The trial includes a randomized controlled portion and an open-label extension, with no indication of phase 2B completion.
community Does anyone know of the actual effectiveness of the DP2 inhibitors?
Setipiprant and Fevipiprant are questioned for their effectiveness in hair maintenance, with skepticism due to lack of convincing results beyond vellus hair growth. The user is satisfied with Minoxidil and Finasteride but is curious about the potential of DP2 inhibitors.
community Pp405 phase 2a clinical results
PP405 shows initial promise for treating androgenetic alopecia, with safety confirmed in early trials, but skepticism remains due to limited data. Further trials are needed to determine its true efficacy and potential market impact.
community mallia therapeutics 8T3 scd83 molecule for ffa/lpp mainly and aga
A user applied the 8T3 product for hair loss, targeting LPP and AGA, and plans to update on its effectiveness. The product uses a saline buffered phosphate vehicle, suitable for those intolerant to ethanolic vehicles.
community Pelage Pharmaceuticals Announces Positive Phase 2a Clinical Trial Results for PP405 in Regenerative Hair Loss Therapy
Pelage Pharmaceuticals announced positive Phase 2a trial results for PP405 in hair loss therapy. The conversation discusses the delay in publishing full results and the need for further trials and approvals.